| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| KPRXKiora Pharmaceuticals, Inc. | 8.05M | 2.19 | 2.52 | 22.47% | -38.12% | 100% | 0.00 | |
| KALAKALA BIO, Inc. | 16.74M | 0.60 | -0.09 | -141.11% | -388.29% | 2.62 | ||
| CLSDClearside Biomedical, Inc. | 5.81M | 1.11 | -0.16 | -79.77% | -7.81% | |||
| OTLKOutlook Therapeutics, Inc. | 33.47M | 0.52 | -0.29 | -25.93% | ||||
| ADVMAdverum Biotechnologies, Inc. | 96.26M | 4.36 | -0.66 | -72.22% | -130.93% | -189.84% | 1.30 | |
| IRDOpus Genetics, Inc. | 143.45M | 2.08 | -0.97 | -42.3% | -466.09% | -11.43% | ||
| SKYESkye Bioscience, Inc. | 30.87M | 0.96 | -1.32 | -156.01% | 0.01 | |||
| ALDXAldeyra Therapeutics, Inc. | 265.32M | 4.41 | -4.69 | -87.71% | 0.22 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 57.03M | 25.82M | 17.45M | 182.95M |
| Revenue Growth % | - | - | - | - | -0.55% | -0.32% | 9.49% |
| Cost of Goods Sold | 1K | 74K | 246K | 2.08M | 955K | 1.59M | 12.83M |
| COGS % of Revenue | - | - | - | 0.04% | 0.04% | 0.09% | 0.07% |
| Gross Profit | -1K | -74K | -246K | 54.95M | 24.86M | 15.85M | 170.13M |
| Gross Margin % | - | - | - | 0.96% | 0.96% | 0.91% | 0.93% |
| Gross Profit Growth % | - | -73% | -2.32% | 224.38% | -0.55% | -0.36% | 9.73% |
| Operating Expenses | 1.35M | 4.22M | 26.74M | 67.11M | 87.57M | 159.01M | 290.7M |
| OpEx % of Revenue | - | - | - | 1.18% | 3.39% | 9.11% | 1.59% |
| Selling, General & Admin | 448K | 1.06M | 7.93M | 25.4M | 44.95M | 108.7M | 237.31M |
| SG&A % of Revenue | - | - | - | 0.45% | 1.74% | 6.23% | 1.3% |
| Research & Development | 901K | 3.16M | 18.83M | 41.71M | 42.62M | 50.31M | 53.39M |
| R&D % of Revenue | - | - | - | 0.73% | 1.65% | 2.88% | 0.29% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -1.35M | -4.3M | -26.98M | -12.16M | -62.71M | -143.16M | -120.57M |
| Operating Margin % | - | - | - | -0.21% | -2.43% | -8.21% | -0.66% |
| Operating Income Growth % | - | -2.18% | -5.28% | 0.55% | -4.16% | -1.28% | 0.16% |
| EBITDA | -1.35M | -4.22M | -26.74M | -11.85M | -62.39M | -142.28M | -119.34M |
| EBITDA Margin % | - | - | - | -0.21% | -2.42% | -8.16% | -0.65% |
| EBITDA Growth % | - | -2.13% | -5.33% | 0.56% | -4.27% | -1.28% | 0.16% |
| D&A (Non-Cash Add-back) | 1K | 74K | 246K | 312K | 326K | 877K | 1.23M |
| EBIT | -1.32M | -4.63M | -26.81M | -13.77M | -60.03M | -132.55M | -107.7M |
| Net Interest Income | 0 | 0 | 0 | 36K | 1.44M | 7.11M | 7.57M |
| Interest Income | 0 | 40K | 188K | 36K | 3.5M | 10.34M | 15.01M |
| Interest Expense | 0 | 40K | 188K | 0 | 2.06M | 3.23M | 7.45M |
| Other Income/Expense | 32K | -371K | 173K | -1.61M | 617K | 7.26M | 5.01M |
| Pretax Income | -1.32M | -4.67M | -26.81M | -13.77M | -62.09M | -135.89M | -115.55M |
| Pretax Margin % | - | - | - | -0.24% | -2.41% | -7.79% | -0.63% |
| Income Tax | 1K | 1K | 1K | 55K | -4K | 0 | 0 |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 1% | 1% | 1% |
| Net Income | -1.32M | -4.67M | -26.81M | -13.83M | -62.09M | -135.89M | -115.55M |
| Net Margin % | - | - | - | -0.24% | -2.41% | -7.79% | -0.63% |
| Net Income Growth % | - | -2.54% | -4.74% | 0.48% | -3.49% | -1.19% | 0.15% |
| Net Income (Continuing) | -1.32M | -4.67M | -26.81M | -13.83M | -62.09M | -135.89M | -115.55M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.31 | -0.24 | -1.32 | -0.67 | -2.52 | -4.62 | -3.07 |
| EPS Growth % | - | 0.23% | -4.5% | 0.49% | -2.76% | -0.83% | 0.34% |
| EPS (Basic) | -0.31 | -0.24 | -1.32 | -0.67 | -2.52 | -4.62 | -3.07 |
| Diluted Shares Outstanding | 4.29M | 19.51M | 20.32M | 20.55M | 24.62M | 29.38M | 37.6M |
| Basic Shares Outstanding | 4.29M | 19.51M | 20.32M | 20.55M | 24.62M | 29.38M | 37.6M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 2.38M | 58.03M | 170.66M | 175.95M | 225.38M | 256.13M | 356.7M |
| Cash & Short-Term Investments | 2.35M | 57.95M | 168.13M | 171.81M | 217.03M | 227.44M | 291.38M |
| Cash Only | 2.35M | 57.95M | 168.13M | 171.33M | 71.66M | 224.95M | 94.82M |
| Short-Term Investments | 0 | 0 | 0 | 483K | 145.37M | 2.5M | 196.56M |
| Accounts Receivable | 4K | 36K | 20K | 92K | 3.58M | 17.71M | 48.06M |
| Days Sales Outstanding | - | - | - | 0.59 | 50.64 | 370.59 | 95.88 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 3.11M | 2.62M |
| Days Inventory Outstanding | - | - | - | - | - | 711.9 | 74.56 |
| Other Current Assets | 20K | 20K | 20K | 0 | 0 | 0 | 0 |
| Total Non-Current Assets | 6K | 286K | 1.32M | 2.96M | 2.49M | 9.36M | 20.29M |
| Property, Plant & Equipment | 6K | 280K | 1.24M | 1.83M | 1.53M | 3.35M | 2.87M |
| Fixed Asset Turnover | - | - | - | 31.18x | 16.85x | 5.21x | 63.84x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 3.87M | 8.33M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 371K | 631K | 3M |
| Other Non-Current Assets | 0 | 6K | 81K | 1.13M | 585K | 1.51M | 6.09M |
| Total Assets | 2.39M | 58.32M | 171.97M | 178.91M | 227.86M | 265.49M | 376.99M |
| Asset Turnover | - | - | - | 0.32x | 0.11x | 0.07x | 0.49x |
| Asset Growth % | - | 23.41% | 1.95% | 0.04% | 0.27% | 0.17% | 0.42% |
| Total Current Liabilities | 179K | 819K | 5.39M | 11.48M | 15.43M | 36.94M | 80.61M |
| Accounts Payable | 175K | 456K | 2.24M | 2.86M | 5.5M | 17.77M | 27.74M |
| Days Payables Outstanding | 63.88K | 2.25K | 3.32K | 502.38 | 2.1K | 4.07K | 789.39 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1K | 0 | 304K | 56K | 0 | 0 | 0 |
| Current Ratio | 13.31x | 70.85x | 31.68x | 15.33x | 14.61x | 6.93x | 4.42x |
| Quick Ratio | 13.31x | 70.85x | 31.68x | 15.33x | 14.61x | 6.85x | 4.39x |
| Cash Conversion Cycle | - | - | - | - | - | -2.99K | -618.95 |
| Total Non-Current Liabilities | 3.56M | 63.5M | 605K | 699K | 19.53M | 31.57M | 71.84M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 19.43M | 29.82M | 71.84M |
| Capital Lease Obligations | 0 | 100K | 549K | 585K | 52K | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 3.56M | 63.4M | 56K | 114K | 48K | 1.75M | 0 |
| Total Liabilities | 3.74M | 64.32M | 5.99M | 12.18M | 34.96M | 68.5M | 152.46M |
| Total Debt | 0 | 164K | 831K | 1.89M | 20.21M | 30.22M | 72.45M |
| Net Debt | -2.35M | -57.79M | -167.3M | -169.44M | -51.45M | -194.73M | -22.37M |
| Debt / Equity | - | - | 0.01x | 0.01x | 0.10x | 0.15x | 0.32x |
| Debt / EBITDA | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - |
| Interest Coverage | - | -107.45x | -143.53x | - | -30.38x | -44.39x | -16.19x |
| Total Equity | -1.35M | -6M | 165.98M | 166.73M | 192.9M | 196.99M | 224.53M |
| Equity Growth % | - | -3.44% | 28.64% | 0% | 0.16% | 0.02% | 0.14% |
| Book Value per Share | -0.32 | -0.31 | 8.17 | 8.11 | 7.84 | 6.70 | 5.97 |
| Total Shareholders' Equity | -1.35M | -6M | 165.98M | 166.73M | 192.9M | 196.99M | 224.53M |
| Common Stock | 1K | 2K | 4K | 4K | 5K | 5K | 6K |
| Retained Earnings | -1.36M | -6.03M | -32.84M | -46.67M | -108.76M | -244.66M | -360.21M |
| Treasury Stock | -9K | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -1K | 0 | 0 | 0 | -74K | -2K | 179K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -1.18M | -3.67M | -21.14M | 3.75M | -49.03M | -117.49M | -83.03M |
| Operating CF Margin % | - | - | - | 0.07% | -1.9% | -6.73% | -0.45% |
| Operating CF Growth % | - | -2.1% | -4.75% | 1.18% | -14.08% | -1.4% | 0.29% |
| Net Income | -1.32M | -4.67M | -26.81M | -13.83M | -62.09M | -135.89M | -115.55M |
| Depreciation & Amortization | 1K | 37K | 96K | 312K | 325K | 877K | 1.23M |
| Stock-Based Compensation | 9K | 18K | 839K | 8.46M | 13.46M | 19.83M | 27.82M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -116K | 457K | 3.28M | 7.44M | 227K | -2.61M | -360K |
| Working Capital Changes | 126K | 485K | 1.46M | 1.37M | -951K | 306K | 3.84M |
| Change in Receivables | -4K | -32K | 16K | -73K | -3.49M | -14.13M | -30.14M |
| Change in Inventory | 0 | 0 | 0 | 0 | 3.49M | -3.11M | -2.05M |
| Change in Payables | 131K | 245K | 3.24M | 3.88M | 821K | 13.24M | 40.34M |
| Cash from Investing | -7K | -175K | -456K | -586K | -144.63M | 140.6M | -199.19M |
| Capital Expenditures | -7K | -175K | -456K | -586K | -506K | -1.5M | -1.57M |
| CapEx % of Revenue | - | - | - | 0.01% | 0.02% | 0.09% | 0.01% |
| Acquisitions | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | -144.12M | -4M | -5M |
| Cash from Financing | 3.56M | 59.45M | 131.77M | 21K | 93.99M | 130.18M | 154.66M |
| Debt Issued (Net) | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - |
| Other Financing | 0 | 0 | 370K | 0 | 0 | 0 | 0 |
| Net Change in Cash | - | - | - | - | - | - | - |
| Free Cash Flow | -1.19M | -3.85M | -21.59M | 3.16M | -49.54M | -123M | -84.59M |
| FCF Margin % | - | - | - | 0.06% | -1.92% | -7.05% | -0.46% |
| FCF Growth % | - | -2.23% | -4.61% | 1.15% | -16.67% | -1.48% | 0.31% |
| FCF per Share | -0.28 | -0.20 | -1.06 | 0.15 | -2.01 | -4.19 | -2.25 |
| FCF Conversion (FCF/Net Income) | 0.90x | 0.79x | 0.79x | -0.27x | 0.79x | 0.86x | 0.72x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 2.88M | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -33.52% | -8.31% | -34.53% | -69.71% | -54.83% |
| Return on Invested Capital (ROIC) | - | - | - | - | -67.8% | -149.43% | -88.47% |
| Gross Margin | - | - | - | 96.36% | 96.3% | 90.87% | 92.99% |
| Net Margin | - | - | - | -24.25% | -240.51% | -778.89% | -63.16% |
| Debt / Equity | - | - | 0.01x | 0.01x | 0.10x | 0.15x | 0.32x |
| Interest Coverage | - | -107.45x | -143.53x | - | -30.38x | -44.39x | -16.19x |
| FCF Conversion | 0.90x | 0.79x | 0.79x | -0.27x | 0.79x | 0.86x | 0.72x |
| Revenue Growth | - | - | - | - | -54.73% | -32.42% | 948.62% |
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Product | - | - | 14.73M | 180.06M |
| Product Growth | - | - | - | 1122.48% |
| License Fees and Collaboration | 2.08M | 955K | 2.72M | 2.89M |
| License Fees and Collaboration Growth | - | -53.98% | 184.61% | 6.48% |
| License and Service | 53.07M | 23.89M | - | - |
| License and Service Growth | - | -54.98% | - | - |
| Collaboration Revenue | 3.96M | 1.92M | - | - |
| Collaboration Revenue Growth | - | -51.44% | - | - |
Tarsus Pharmaceuticals, Inc. (TARS) reported $366.1M in revenue for fiscal year 2024.
Tarsus Pharmaceuticals, Inc. (TARS) grew revenue by 948.6% over the past year. This is strong growth.
Tarsus Pharmaceuticals, Inc. (TARS) reported a net loss of $81.2M for fiscal year 2024.
Tarsus Pharmaceuticals, Inc. (TARS) has a return on equity (ROE) of -54.8%. Negative ROE indicates the company is unprofitable.
Tarsus Pharmaceuticals, Inc. (TARS) had negative free cash flow of $62.5M in fiscal year 2024, likely due to heavy capital investments.